Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07137884) titled 'Anlotinib Hydrochloride Capsules in Maintenance Treatment for Intermediate-High Risk Rhabdomyosarcoma in Children' on Aug. 15.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Sun Yat-sen University
Condition:
Rhabdomyosarcoma Recurrent
Maintenance Treatment
Intervention:
Drug: Anlotinib+Cyclophosphamide+Vinorelbine
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: October 1, 2025
Target Sample Size: 150
Countries of Recruitment:
China
To know more...